Amoebiasis (Amoebic Dysentery)
Summary
Amoebiasis is infection with the protozoan parasite Entamoeba histolytica, transmitted via the faecal-oral route through ingestion of cysts in contaminated food or water. Infection ranges from asymptomatic carriage to invasive disease causing amoebic colitis (bloody diarrhoea) and extraintestinal spread, most commonly amoebic liver abscess (ALA). E. histolytica is responsible for approximately 100,000 deaths annually worldwide, primarily in developing countries with poor sanitation. Treatment requires both a tissue amoebicide (metronidazole) for invasive disease and a luminal amoebicide (paromomycin or diloxanide furoate) to eradicate intestinal cysts and prevent relapse or transmission.
Key Facts
- Prevalence: 500 million infected globally; 50 million symptomatic cases/year
- Transmission: Faecal-oral (contaminated water/food); cysts are infectious
- Invasive disease: 10% of infected individuals develop invasive disease
- ALA: 80% occur in young adult males; typically right lobe
- Diagnosis: Stool microscopy (trophozoites with ingested RBCs), serology, PCR
- Key treatment: Metronidazole (tissue) + Paromomycin (luminal) — both needed
Clinical Pearls
Anchovy Sauce Pus: Aspirate from amoebic liver abscess classically has a reddish-brown "anchovy sauce" appearance and is sterile on bacterial culture (no bacteria, only amoebae).
Two Drugs, Two Jobs: Metronidazole kills trophozoites in tissues but does NOT eliminate cysts in the gut lumen. Always follow with a luminal agent (paromomycin or diloxanide) to eradicate cysts and prevent relapse.
Erythrophagocytosis: Trophozoites containing ingested red blood cells are pathognomonic for E. histolytica and distinguish it from non-pathogenic Entamoeba dispar.
Why This Matters Clinically
Amoebiasis is a major cause of diarrhoeal illness in travellers and immigrants from endemic areas. Failure to complete treatment with a luminal agent leads to relapse and continued transmission. Amoebic liver abscess can be life-threatening if it ruptures but has excellent outcomes with appropriate treatment.
Incidence & Prevalence
- Global prevalence: 500 million people colonised
- Symptomatic infections: 50 million per year
- Deaths: 40,000-100,000 per year (third leading parasitic cause of death)
- Travellers: Common in returning travellers from endemic areas
Demographics
| Factor | Details |
|---|---|
| Geography | Endemic in Central/South America, Africa, South Asia |
| Age | All ages; ALA peaks in 20-40 year olds |
| Sex | ALA 7-10x more common in males |
| Risk groups | Travellers, immigrants, MSM, institutions |
Risk Factors
| Factor | Impact |
|---|---|
| Travel to endemic areas | Primary risk |
| Poor sanitation | Higher exposure |
| Immunosuppression | Severe disease |
| Malnutrition | Worse outcomes |
| Male sex | Higher risk of ALA |
Mechanism
Step 1: Transmission and Excystation
- Ingestion of mature cysts in contaminated food/water
- Cysts resistant to gastric acid; excyst in small intestine
- Each cyst releases 8 trophozoites
Step 2: Colonisation
- Trophozoites colonise large intestine
- Most remain as commensals (asymptomatic carriage)
- May encyst and be shed in faeces (continuing transmission)
Step 3: Tissue Invasion (10% of infections)
- Contact-dependent cytolysis via amoebapore (pore-forming peptide)
- Cysteine proteases degrade extracellular matrix
- Trophozoites invade colonic mucosa ("flask-shaped" ulcers)
- Causes amoebic colitis with bloody diarrhoea
Step 4: Extraintestinal Spread
- Haematogenous spread via portal circulation
- Liver most common site (right lobe in 80%)
- Forms abscess with liquefactive necrosis
- May spread to lung, brain (rare)
Classification
| Form | Definition | Features |
|---|---|---|
| Asymptomatic carriage | Colonisation without invasion | Cyst shedding |
| Amoebic colitis | Invasive intestinal disease | Bloody diarrhoea, ulcers |
| Amoebic liver abscess | Extraintestinal spread | RUQ pain, fever, hepatomegaly |
| Fulminant colitis | Necrotising, transmural | Perforation risk |
| Amoeboma | Granulomatous mass | Mimics malignancy |
Symptoms
Amoebic Colitis:
Amoebic Liver Abscess:
Signs
Red Flags
[!CAUTION] Red Flags — Urgent assessment required if:
- Severe bloody diarrhoea with dehydration
- Signs of peritonitis (rigid abdomen, guarding) — perforation or rupture
- Toxic megacolon (abdominal distension, systemic illness)
- Large liver abscess (greater than 10cm) at risk of rupture
- Neurological symptoms (cerebral amoebiasis)
Structured Approach
General:
- Vital signs (fever, tachycardia, hypotension)
- Hydration status
- Signs of weight loss
Abdominal:
- Tenderness (RIF in colitis; RUQ in ALA)
- Hepatomegaly (ALA)
- Percussion tenderness over liver
- Signs of peritonitis
Respiratory:
- Reduced breath sounds right base (reactive effusion or rupture)
Special Tests
| Test | Technique | Positive Finding | Purpose |
|---|---|---|---|
| Hepatic percussion | Percuss right upper quadrant | Enlarged, tender liver | ALA detection |
| Punch tenderness | Gentle fist percussion over liver | Pain | Suggests abscess |
| Rectal exam | Digital examination | Blood, tenderness | Colitis assessment |
First-Line
- Stool microscopy — Fresh sample; look for trophozoites with ingested RBCs
- Stool antigen test — E. histolytica-specific antigen detection
- Serology — Elevated in 95% of ALA
Laboratory Tests
| Test | Expected Finding | Purpose |
|---|---|---|
| FBC | Leukocytosis (no eosinophilia) | Inflammatory response |
| LFTs | Elevated ALP; mildly elevated transaminases | Liver involvement |
| CRP | Elevated | Inflammatory marker |
| Stool M/C/S | Trophozoites with RBC ingestion | Definitive diagnosis |
| Amoebic serology | Positive in 95% of ALA, 70% of colitis | Extra-intestinal disease |
| Stool PCR | E. histolytica DNA | Distinguishes from E. dispar |
Imaging
| Modality | Findings | Indication |
|---|---|---|
| Ultrasound liver | Round, hypoechoic lesion (usually right lobe) | First-line for ALA |
| CT abdomen | Well-defined rim-enhancing liver lesion | ALA confirmation, complication assessment |
| CXR | Right-sided pleural effusion, elevated hemidiaphragm | Thoracic extension |
Diagnostic Aspiration (if uncertain)
- "Anchovy sauce" pus (reddish-brown, odourless)
- Sterile on bacterial culture
- Trophozoites rarely seen (usually at abscess wall)
Management Algorithm
SUSPECTED AMOEBIASIS
↓
┌─────────────────────────────────────────┐
│ CLINICAL PRESENTATION │
├─────────────────────────────────────────┤
│ BLOODY DIARRHOEA → Amoebic colitis │
│ RUQ PAIN + FEVER → Amoebic liver abs │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ INVESTIGATIONS │
│ Stool: Microscopy, antigen, PCR │
│ Serology: Amoebic antibodies │
│ Imaging: US/CT for liver abscess │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ TREATMENT (BOTH REQUIRED) │
├─────────────────────────────────────────┤
│ 1. TISSUE AMOEBICIDE │
│ Metronidazole 800mg TDS × 5-10d │
│ │
│ 2. LUMINAL AMOEBICIDE (after Metro) │
│ Paromomycin 500mg TDS × 7d │
│ OR Diloxanide 500mg TDS × 10d │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ ASPIRATION (Selective) │
│ > 10cm abscess │
│ Left lobe (risk of pericardial rupture)│
│ No response to treatment (48-72h) │
│ Uncertain diagnosis │
└─────────────────────────────────────────┘
Medical Management
Tissue Amoebicide (Kills Invasive Trophozoites):
| Drug | Dose | Duration | Notes |
|---|---|---|---|
| Metronidazole | 800mg TDS (or 750mg TDS) | 5-10 days | First-line for colitis and ALA |
| Tinidazole | 2g OD | 3-5 days | Alternative; better tolerated |
Luminal Amoebicide (Eliminates Intestinal Cysts):
| Drug | Dose | Duration | Notes |
|---|---|---|---|
| Paromomycin | 500mg TDS | 7 days | First-line luminal agent |
| Diloxanide furoate | 500mg TDS | 10 days | Alternative |
| Iodoquinol | 650mg TDS | 20 days | Third-line |
[!IMPORTANT] Always give luminal agent after tissue amoebicide to eliminate cysts and prevent relapse/transmission.
Surgical/Interventional Management
Aspiration/Drainage Indications:
- Abscess greater than 10cm or high risk of rupture
- Left lobe abscess (risk of pericardial rupture)
- Poor response to medication after 48-72 hours
- Uncertain diagnosis (need to exclude pyogenic abscess)
Surgical Indications:
- Bowel perforation
- Toxic megacolon
- Ruptured abscess with peritonitis
Disposition
- Admit if: Severe colitis, ALA requiring drainage, dehydration, complications
- Discharge if: Mild-moderate disease, tolerating oral treatment
- Follow-up: Repeat stool examination to confirm clearance; monitor abscess resolution on imaging
Intestinal Complications
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Fulminant colitis | 2-5% | Massive bloody diarrhoea, shock | Surgical resection |
| Toxic megacolon | 1-2% | Abdominal distension, systemic toxicity | Surgery |
| Perforation | 1% | Peritonitis | Emergency surgery |
| Amoeboma | Rare | Mass lesion mimicking cancer | Metronidazole; biopsy if uncertain |
Liver Abscess Complications
- Rupture into peritoneum (6-9%)
- Rupture into pleura, pericardium, or bronchus
- Secondary bacterial infection
- Hepatic vein thrombosis
Rare Complications
- Cerebral amoebiasis (brain abscess)
- Cutaneous amoebiasis
- Genitourinary amoebiasis
Natural History
- Asymptomatic carriage: May persist for years
- Untreated ALA: High mortality from rupture or sepsis
- With treatment: Excellent outcomes
Outcomes with Treatment
| Variable | Outcome |
|---|---|
| Colitis cure rate | Greater than 95% |
| ALA cure rate | 90-95% with medication alone |
| Mortality (treated ALA) | Less than 1% |
| Mortality (ruptured ALA) | 20-30% |
Prognostic Factors
Good Prognosis:
- Early diagnosis
- Right lobe abscess
- Prompt treatment
- No complications
Poor Prognosis:
- Large abscess (greater than 10cm)
- Left lobe abscess (pericardial rupture risk)
- Multiple abscesses
- Delayed treatment
- Rupture
Key Guidelines
- CDC Guidelines — Diagnosis and treatment of amoebiasis. cdc.gov/parasites/amebiasis
- WHO Guidelines — Endemic parasitic diseases management.
- UpToDate/Sanford Guide — Current treatment recommendations.
Key Studies
Stanley SL (2003) — Pathogenesis of amoebiasis
- Review of invasion mechanisms and tissue damage
- Clinical Impact: Foundation for understanding pathophysiology
Blessmann et al. (2002) — PCR for E. histolytica
- Demonstrated importance of distinguishing E. histolytica from E. dispar
- Clinical Impact: PCR becomes diagnostic standard
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Metronidazole for ALA | 1b | Multiple RCTs |
| Luminal agent after tissue agent | 2a | Cohort studies, consensus |
| Aspiration for large abscess | 2b | Cohort studies |
What is Amoebiasis?
Amoebiasis is an infection caused by a tiny parasite called Entamoeba histolytica. You catch it by swallowing contaminated water or food, usually in parts of the world with poor sanitation. The parasite can cause bloody diarrhoea by infecting your gut, or it can spread to your liver and form an abscess (a collection of pus).
Why does it matter?
Most people who catch the parasite have no symptoms, but about 1 in 10 develop illness. Amoebic dysentery causes painful bloody diarrhoea. A liver abscess can be very serious if it bursts. The good news is that with the right antibiotics, the infection is completely curable.
How is it treated?
- Two medications are needed:
- First, metronidazole (an antibiotic) kills the parasites causing damage
- Then, a second medicine (paromomycin) clears the remaining parasites from your gut
- If you have a liver abscess, you may need drainage with a needle if it's very large.
- Rest and fluids are important if you have diarrhoea.
What to expect
- Symptoms usually improve within 48-72 hours of starting treatment
- You must complete both courses of medicine to prevent the infection coming back
- Liver abscesses typically resolve over weeks to months on imaging
When to seek help
See a doctor urgently if you have:
- Bloody diarrhoea, especially after travel to developing countries
- Severe abdominal pain, especially on the right side under your ribs
- High fever with abdominal pain
- Signs of dehydration (dizziness, not passing urine)
Primary Guidelines
- Centers for Disease Control and Prevention. Amebiasis. cdc.gov/parasites/amebiasis
Key Studies
- Stanley SL Jr. Amoebiasis. Lancet. 2003;361(9362):1025-34. PMID: 12660071
- Haque R, et al. Amebiasis. N Engl J Med. 2003;348(16):1565-73. PMID: 12700377
- Blessmann J, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol. 2002;40(12):4413-7. PMID: 12454130
Further Resources
- CDC Travellers' Health: cdc.gov/travel
- WHO Parasitic Diseases: who.int
- London School of Hygiene & Tropical Medicine: lshtm.ac.uk
Last Reviewed: 2025-12-24 | MedVellum Editorial Team
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.